Abstract 829
Background
there is little solid evidence of the effectiveness of psychological interventions using MBRS program for those with advanced cancer. The objective of this study was to evaluate the acceptability and potential benefits of MBSR for pt with cancer pain in early palliative care.
Methods
Main inclusion criteria were: advanced cancer pt in early palliative care; NRS >3;PS >60% according to Karnosky, informed consent. 20 advanced cancer pt were enrolled. Each session included different forms of mindfulness meditation practice, mindful awareness during yoga postures and mindfulness during stressful situations. Participants enter upon enrolling into a commitment to carry out daily 45-min homework assignments .A dedicate nurse with experience in palliative care attended each mindfulness session. Primary outcome was total pain at the end of MBSR intervention evaluated by both VAS and ESAS scales. Secondary outcome was mood state change evaluated by POMS questionnaire. Satisfaction of treatment and compliance were also evaluated. All questionnaires along with a form for collecting personal and clinical data were administered by nurse at baseline and at the end of MBSR intervention.
Results
19 out of 20 were female with median age 54 years old. 56% were receiving morphine for cancer pain. Preliminary results did show slight reduction in total pain score which however was not statistically significant. The POMS test showed significant changes in the mean scores indicating a statistically significant improvement of mood at the end of mindfulness sessions. Compliance program and homework was 70% while pt satisfaction was 78%.
Conclusions
This program appears to be feasible and well accepted. The improvements in the mood state suggests that the mindfulness techniques could play a role in helping patients to reduce mood disturbance. The role of nurse was optimal to allow critically ill patients to participate in MBRS and to guarantee adherence and satisfaction. Moreover nurse was very helful to support the mindfulness trainer in managing cancer patients according to their physical needs. Finally the presence of nurse has been evaluated by patients as part of cancer caring.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fabrizio Artioli.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2743 - The Impact of Targeted Therapies and Immunotherapy in Melanoma Brain Metastases: a Systematic Review and Meta-Analysis
Presenter: Mario Mandala
Session: Poster Display session 3
Resources:
Abstract
5479 - Intracranial Anti-Tumor Activity in Melanoma Brain Metastases with Encorafenib Plus Binimetinib: A Multicenter, Retrospective Analysis
Presenter: Jose Lutzky
Session: Poster Display session 3
Resources:
Abstract
3560 - Outcomes of Patients with Melanoma Brain Metastases (MBM) Treated with Standard of Care Therapy After Being Excluded from MBM-Specific Clinical Trials
Presenter: Kourtney Holbrook
Session: Poster Display session 3
Resources:
Abstract
3175 - The analysis of current treatment outcomes in melanoma patients with brain metastases
Presenter: Joanna Placzke
Session: Poster Display session 3
Resources:
Abstract
4550 - A multivariate model to define prognostic groups among patients with melanoma brain metastases: a 10-year retrospective cohort study
Presenter: Giacomo Pelizzari
Session: Poster Display session 3
Resources:
Abstract
4191 - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumors.
Presenter: Robert Ferguson
Session: Poster Display session 3
Resources:
Abstract
1625 - Final Results from Phase II of Combination with Canerpaturev (formerly HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Unresectable or Metastatic Melanoma in 2nd-or later line treatment
Presenter: Kenji Yokota
Session: Poster Display session 3
Resources:
Abstract
5346 - Evaluating polygenic risk score prediction model for melanoma prognosis
Presenter: Miriam Potrony
Session: Poster Display session 3
Resources:
Abstract
5477 - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy
Presenter: Maria Grazia Vitale
Session: Poster Display session 3
Resources:
Abstract
3469 - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.
Presenter: Celine Boutros
Session: Poster Display session 3
Resources:
Abstract